| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
| Targets |
D-Mannosamine hydrochloride targets mannose receptors on cell surfaces. By blocking mannose receptors, it can modulate cellular interactions and immune responses. It is also involved in glycosaminoglycan biosynthesis pathways, serving as a key intermediate in the formation of extracellular matrix components.
|
|---|---|
| ln Vitro |
In vitro, D-mannosamine hydrochloride is used to study the role of mannose receptors in cellular processes. It can block the binding of mannose-containing ligands to these receptors, thereby inhibiting mannose receptor-mediated endocytosis and signaling. The compound is also used in studies of glycosaminoglycan synthesis and the development of bioadhesive drug delivery systems.
|
| ln Vivo |
In vivo, D-mannosamine hydrochloride is used in the development of mannosylated liposomes for bioadhesive oral drug delivery via M cells of Peyer's patches. The compound's ability to target mannose receptors on these cells facilitates the uptake of drug-loaded liposomes, enhancing oral bioavailability. It is also used in metabolic studies of amino sugar metabolism.
|
| Enzyme Assay |
In vitro enzyme assays for D-mannosamine hydrochloride typically measure the activity of enzymes involved in amino sugar metabolism, such as glucosamine-6-phosphate synthase or mannosamine kinases. The compound is used as a substrate or inhibitor to study enzyme kinetics and the effects of various modulators on amino sugar biosynthesis pathways.
|
| Cell Assay |
In vitro cell experiments with D-mannosamine hydrochloride involve treating cell lines with the compound to study mannose receptor function or to evaluate drug delivery systems. Cells such as macrophages or intestinal epithelial cells are cultured with the compound to assess receptor binding, uptake, and downstream signaling. The compound may also be used in the preparation of mannosylated liposomes for targeted drug delivery studies.
|
| Animal Protocol |
In vivo animal experiments with D-mannosamine hydrochloride involve oral administration of mannosylated liposomes formulated with the compound to study their bioadhesive properties and drug delivery efficiency. Animal models such as rats or mice are used to assess the pharmacokinetics, biodistribution, and therapeutic efficacy of the mannosylated formulations. Tissue samples are collected and analyzed to evaluate the targeting of M cells in Peyer's patches.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for D-mannosamine hydrochloride are limited. As an amino sugar, it is expected to be absorbed from the gastrointestinal tract and metabolized through amino sugar pathways. The compound's ability to target mannose receptors may enhance its accumulation in tissues expressing these receptors. The hydrochloride salt form improves aqueous solubility for laboratory use.
|
| Toxicity/Toxicokinetics |
Toxicological data for D-mannosamine hydrochloride are limited. As a naturally occurring amino sugar derivative, it is expected to have low toxicity at physiological concentrations. The compound is intended for research use only and not for human consumption. Comprehensive toxicological studies have not been performed.
|
| Additional Infomation |
D-(+)-galactosamine is a hexose.
See also: D-galactosamine (note moved to); glucosamine hydrochloride (note moved to). D-Mannosamine hydrochloride is a research compound with applications in glycobiology, drug delivery, and glycosaminoglycan research. It is used as a precursor in the synthesis of glycosaminoglycans and as a tool to study mannose receptor function. No clinical trials or approved therapeutic indications exist for this compound. Its mechanism of action involves the blockade of mannose receptors and participation in amino sugar metabolism. |
| Molecular Formula |
C6H14CLNO5
|
|---|---|
| Molecular Weight |
215.63
|
| Exact Mass |
215.056
|
| CAS # |
5505-63-5
|
| PubChem CID |
5351447
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
532.5ºC at 760 mmHg
|
| Melting Point |
168ºC (dec.)
|
| Flash Point |
275.8ºC
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
13
|
| Complexity |
142
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C([C@H]([C@H]([C@@H]([C@@H](C=O)N)O)O)O)O.Cl
|
| InChi Key |
CBOJBBMQJBVCMW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H13NO5.ClH/c7-3(1-8)5(11)6(12)4(10)2-9;/h1,3-6,9-12H,2,7H2;1H
|
| Chemical Name |
2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 25 mg/mL (115.94 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.59 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (11.59 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (11.59 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.6376 mL | 23.1879 mL | 46.3757 mL | |
| 5 mM | 0.9275 mL | 4.6376 mL | 9.2751 mL | |
| 10 mM | 0.4638 mL | 2.3188 mL | 4.6376 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
